

Digital Therapeutics for ADHD Market Forecasts to 2034 – Global Analysis By Product Type (Prescription Digital Therapeutics, Non-Prescription Digital Therapeutics, Software-Based Therapeutic Programs, Video Game-Based Therapeutics, Mobile Application-Based Therapeutics, and Web-Based Therapeutic Platforms), Age Group, Delivery Platform, Business Model, Application, End User and By Geography

<https://marketpublishers.com/r/DC4A7DF46EFEEN.html>

Date: September 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: DC4A7DF46EFEEN

Abstracts

According to Statistics MRC, the Global Digital Therapeutics for ADHD Market is accounted for \$1.5 billion in 2026 and is expected to reach \$6.8 billion by 2034 growing at a CAGR of 20.7% during the forecast period. Digital therapeutics for ADHD are evidence-based software applications delivered via smartphones, tablets, personal computers, and wearable devices that provide therapeutic interventions for attention deficit hyperactivity disorder through mechanisms including cognitive training, behavioral therapy, neurofeedback, and attention regulation exercises delivered in gamified and interactive formats. These prescription and non-prescription digital interventions are designed to improve attention capacity, impulse control, executive function, and behavioral self-regulation through repeated engagement with scientifically validated therapeutic protocols, often prescribed in conjunction with pharmacotherapy or as standalone treatment alternatives for patients seeking non-pharmacological ADHD management options.

Market Dynamics:

Driver:

ADHD Medication Access Barriers

Access barriers to traditional ADHD medications, including stimulant shortages, prescription regulatory restrictions, side effect concerns, and patient preference for non-pharmacological treatment options, are driving significant demand for digital therapeutics as viable alternative or complementary treatment approaches for attention deficit hyperactivity disorder. The increasing diagnosis rates of ADHD across pediatric, adolescent, and adult populations have created substantial treatment demand that conventional medication supply chains cannot fully satisfy, while patient concerns regarding stimulant side effects have motivated interest in FDA-cleared digital treatment options. Healthcare provider recognition of digital therapeutics as evidence-based interventions is expanding prescription and recommendation patterns.

Restraint:

Reimbursement Coverage Limitations

Limited reimbursement coverage and payer acceptance of digital therapeutics for ADHD represent significant market restraints, as many health insurance plans and government healthcare programs have not established adequate coverage policies for prescription digital therapeutics, creating out-of-pocket cost barriers that restrict patient access and limit market expansion. Reimbursement approval processes require extensive clinical evidence and cost-effectiveness data that digital therapeutic companies must generate through expensive clinical trials, while healthcare provider prescribing patterns remain cautious without established reimbursement pathways. The fragmented US payer landscape and diverse international reimbursement systems create market access complexity for digital therapeutic companies.

Opportunity:

Pediatric Mental Health Integration

Integration with pediatric mental health services presents a significant market opportunity for ADHD digital therapeutics, as the established demand for pediatric ADHD treatment creates ready adoption pathways through children's hospitals, behavioral health centers, school-based health services, and pediatric mental health specialist networks. Digital therapeutics deployed in clinical settings enable continuous therapeutic engagement between clinical appointments while providing objective performance data for treatment monitoring and adjustment. The growing emphasis on pediatric mental health infrastructure investment, including school-based mental health services and telehealth platforms, is expanding market access points for ADHD digital therapeutic products.

Threat:

Competition from Wellness Apps

Competition from free or low-cost wellness applications offering attention training and cognitive exercises without clinical evidence requirements constitutes a persistent market threat, as consumers often cannot distinguish between clinically validated prescription digital therapeutics and general wellness apps that lack scientific substantiation for ADHD-specific therapeutic claims. The proliferation of attention-focused applications in app stores creates consumer confusion and price pressure on evidence-based digital therapeutics, while limited healthcare provider awareness of product differentiation between wellness apps and regulated digital therapeutics restricts prescription adoption. Regulatory enforcement against unsubstantiated clinical claims in wellness apps remains inconsistent across jurisdictions.

Covid-19 Impact:

COVID-19 significantly accelerated the digital therapeutics for ADHD market through widespread adoption of telehealth services, increased remote monitoring capabilities, and expanded recognition of digital interventions as essential healthcare tools during pandemic-related healthcare access restrictions. The pandemic increased ADHD diagnosis and treatment demand as remote work, online schooling, and pandemic-related stress exacerbated attention and executive function challenges across populations. Post-pandemic structural impacts include permanent acceptance of digital therapeutics in healthcare delivery, expanded insurance coverage recognition, and integration of digital mental health tools into mainstream ADHD treatment protocols.

The prescription digital therapeutics segment is expected to be the largest during the forecast period

The prescription digital therapeutics segment is expected to account for the largest market share during the forecast period, due to the FDA clearance of prescription digital therapeutics for ADHD treatment generating clinical credibility, healthcare provider confidence, and patient trust in regulated digital interventions with demonstrated safety and efficacy evidence. Prescription digital therapeutics benefit from established physician prescribing patterns that integrate digital interventions with conventional ADHD treatment protocols, while reimbursement coverage is more likely for FDA-cleared therapeutic products compared to unregulated wellness applications. The prescription requirement creates clinical oversight and patient engagement pathways that optimize treatment outcomes and support market growth.

The mobile application-based therapeutics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mobile application-based therapeutics segment is predicted to witness the highest growth rate, driven by the ubiquitous availability of

smartphones and the convenience, accessibility, and engagement advantages of mobile-delivered therapeutic interventions that support daily ADHD management in real-world contexts. Mobile application therapeutics enable continuous patient engagement through push notifications, progress tracking, and gamified interfaces that increase treatment adherence compared to clinic-based or web-based alternatives. The scalability of mobile application distribution through app stores and digital prescription systems enables rapid market expansion and reduced incremental costs per patient.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest diagnosed ADHD prevalence rates, established regulatory framework for prescription digital therapeutics through the FDA, favorable reimbursement environment for digital health interventions, and concentration of digital therapeutic companies including Akili, Inc. and Pear Therapeutics, Inc. The United States leads regional demand through strong clinical adoption of digital therapeutics, healthcare innovation culture, and substantial investment in digital mental health solutions from venture capital and established healthcare companies. Federal recognition of digital therapeutics as reimbursable health interventions is expanding market access.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to increasing ADHD diagnosis awareness, growing mental health acceptance across Asian societies, rising healthcare spending, and expanding digital health infrastructure in China, Japan, South Korea, and Australia. China's digital health policy emphasis and growing recognition of pediatric mental health needs are driving institutional interest in ADHD digital therapeutics, while telemedicine expansion increases access to specialized ADHD diagnosis and treatment in underserved regions. Regional development of culturally adapted digital therapeutics and local language applications is supporting market penetration.

Key players in the market

Some of the key players in Digital Therapeutics for ADHD Market include Akili, Inc., Pear Therapeutics, Inc., Big Health, Inc., Limbix Health, Inc., EndeavorRx, Monument Therapeutics, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Medtronic plc, Omada Health, Inc., DarioHealth Corp., Click Therapeutics, Inc., Woebot Health, Headspace Health, Better Therapeutics, Inc., X2AI, Inc., and Cognoa, Inc.

Key Developments:

In August 2026, Akili, Inc. received expanded FDA clearance for its pediatric ADHD digital therapeutic, enabling broader clinical adoption and improving access to digital treatment options for children with ADHD.

In July 2026, Pear Therapeutics, Inc. announced positive clinical trial results for its adult ADHD digital therapeutic, demonstrating significant symptom improvement and strengthening evidence supporting digital interventions for adult ADHD management.

In June 2026, Click Therapeutics, Inc. launched a new mobile-based ADHD therapeutic targeting executive function deficits with gamified cognitive training modules, supporting personalized treatment and improving engagement among patients.

Product Types Covered:

Prescription Digital Therapeutics

Non-Prescription Digital Therapeutics

Software-Based Therapeutic Programs

Video Game-Based Therapeutics

Mobile Application-Based Therapeutics

Web-Based Therapeutic Platforms

Age Groups Covered:

Children

Adolescents

Adults

Older Adults

Delivery Platforms Covered:

Smartphones

Tablets

Personal Computers

Wearable Devices

Web-Based Platforms

Business Models Covered:

Subscription-Based

One-Time Purchase

Reimbursement-Based

Employer-Sponsored

Healthcare Provider-Sponsored

Applications Covered:

Attention Training

Impulse Control

Cognitive Function Improvement

Behavioral Management

Medication Adherence Support

Remote Patient Monitoring

Other Applications

End Users Covered:

Hospitals and Clinics

Behavioral Health Centers

Academic and Research Institutions

Homecare Settings

Individual Users

Other End Users

Regions Covered:

North America

United States

Canada

Mexico

Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

Belgium

Sweden

Switzerland

Poland

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Thailand

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

Rest of the World (RoW)

Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

Africa

South Africa

Egypt

Morocco

Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

- 1.1 Market Snapshot and Key Highlights
- 1.2 Growth Drivers, Challenges, and Opportunities
- 1.3 Competitive Landscape Overview
- 1.4 Strategic Insights and Recommendations

2 RESEARCH FRAMEWORK

- 2.1 Study Objectives and Scope
- 2.2 Stakeholder Analysis
- 2.3 Research Assumptions and Limitations
- 2.4 Research Methodology
 - 2.4.1 Data Collection (Primary and Secondary)
 - 2.4.2 Data Modeling and Estimation Techniques
 - 2.4.3 Data Validation and Triangulation
 - 2.4.4 Analytical and Forecasting Approach

3 MARKET DYNAMICS AND TREND ANALYSIS

- 3.1 Market Definition and Structure
- 3.2 Key Market Drivers
- 3.3 Market Restraints and Challenges
- 3.4 Growth Opportunities and Investment Hotspots
- 3.5 Industry Threats and Risk Assessment
- 3.6 Technology and Innovation Landscape
- 3.7 Emerging and High-Growth Markets
- 3.8 Regulatory and Policy Environment
- 3.9 Impact of COVID-19 and Recovery Outlook

4 COMPETITIVE AND STRATEGIC ASSESSMENT

- 4.1 Porter's Five Forces Analysis
 - 4.1.1 Supplier Bargaining Power
 - 4.1.2 Buyer Bargaining Power
 - 4.1.3 Threat of Substitutes
 - 4.1.4 Threat of New Entrants

- 4.1.5 Competitive Rivalry
- 4.2 Market Share Analysis of Key Players
- 4.3 Product Benchmarking and Performance Comparison

5 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY PRODUCT TYPE

- 5.1 Prescription Digital Therapeutics
- 5.2 Non-Prescription Digital Therapeutics
- 5.3 Software-Based Therapeutic Programs
- 5.4 Video Game-Based Therapeutics
- 5.5 Mobile Application-Based Therapeutics
- 5.6 Web-Based Therapeutic Platforms

6 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY AGE GROUP

- 6.1 Children
- 6.2 Adolescents
- 6.3 Adults
- 6.4 Older Adults

7 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY DELIVERY PLATFORM

- 7.1 Smartphones
- 7.2 Tablets
- 7.3 Personal Computers
- 7.4 Wearable Devices
- 7.5 Web-Based Platforms

8 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY BUSINESS MODEL

- 8.1 Subscription-Based
- 8.2 One-Time Purchase
- 8.3 Reimbursement-Based
- 8.4 Employer-Sponsored
- 8.5 Healthcare Provider-Sponsored

9 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY APPLICATION

- 9.1 Attention Training
- 9.2 Impulse Control
- 9.3 Cognitive Function Improvement
- 9.4 Behavioral Management
- 9.5 Medication Adherence Support
- 9.6 Remote Patient Monitoring
- 9.7 Other Applications

10 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY END USER

- 10.1 Hospitals and Clinics
- 10.2 Behavioral Health Centers
- 10.3 Academic and Research Institutions
- 10.4 Homecare Settings
- 10.5 Individual Users
- 10.6 Other End Users

11 GLOBAL DIGITAL THERAPEUTICS FOR ADHD MARKET, BY GEOGRAPHY

- 11.1 North America
 - 11.1.1 United States
 - 11.1.2 Canada
 - 11.1.3 Mexico
- 11.2 Europe
 - 11.2.1 United Kingdom
 - 11.2.2 Germany
 - 11.2.3 France
 - 11.2.4 Italy
 - 11.2.5 Spain
 - 11.2.6 Netherlands
 - 11.2.7 Belgium
 - 11.2.8 Sweden
 - 11.2.9 Switzerland
 - 11.2.10 Poland
 - 11.2.11 Rest of Europe
- 11.3 Asia Pacific
 - 11.3.1 China
 - 11.3.2 Japan
 - 11.3.3 India

- 11.3.4 South Korea
- 11.3.5 Australia
- 11.3.6 Indonesia
- 11.3.7 Thailand
- 11.3.8 Malaysia
- 11.3.9 Singapore
- 11.3.10 Vietnam
- 11.3.11 Rest of Asia Pacific
- 11.4 South America
 - 11.4.1 Brazil
 - 11.4.2 Argentina
 - 11.4.3 Colombia
 - 11.4.4 Chile
 - 11.4.5 Peru
 - 11.4.6 Rest of South America
- 11.5 Rest of the World (RoW)
 - 11.5.1 Middle East
 - 11.5.1.1 Saudi Arabia
 - 11.5.1.2 United Arab Emirates
 - 11.5.1.3 Qatar
 - 11.5.1.4 Israel
 - 11.5.1.5 Rest of Middle East
 - 11.5.2 Africa
 - 11.5.2.1 South Africa
 - 11.5.2.2 Egypt
 - 11.5.2.3 Morocco
 - 11.5.2.4 Rest of Africa

12 STRATEGIC MARKET INTELLIGENCE

- 12.1 Industry Value Network and Supply Chain Assessment
- 12.2 White-Space and Opportunity Mapping
- 12.3 Product Evolution and Market Life Cycle Analysis
- 12.4 Channel, Distributor, and Go-to-Market Assessment

13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES

- 13.1 Mergers and Acquisitions
- 13.2 Partnerships, Alliances, and Joint Ventures

13.3 New Product Launches and Certifications

13.4 Capacity Expansion and Investments

13.5 Other Strategic Initiatives

14 COMPANY PROFILES

14.1 Akili, Inc.

14.2 Pear Therapeutics, Inc.

14.3 Big Health, Inc.

14.4 Limbix Health, Inc.

14.5 EndeavorRx

14.6 Monument Therapeutics

14.7 Otsuka Pharmaceutical Co., Ltd.

14.8 Takeda Pharmaceutical Company Limited

14.9 Medtronic plc

14.10 Omada Health, Inc.

14.11 DarioHealth Corp.

14.12 Click Therapeutics, Inc.

14.13 Woebot Health

14.14 Headspace Health

14.15 Better Therapeutics, Inc.

14.16 X2AI, Inc.

14.17 Cognoa, Inc.

List Of Tables

LIST OF TABLES

Table 1 Global Digital Therapeutics for ADHD Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Digital Therapeutics for ADHD Market Outlook, By Product Type (2023-2034) (\$MN)

Table 3 Global Digital Therapeutics for ADHD Market Outlook, By Prescription Digital Therapeutics (2023-2034) (\$MN)

Table 4 Global Digital Therapeutics for ADHD Market Outlook, By Non-Prescription Digital Therapeutics (2023-2034) (\$MN)

Table 5 Global Digital Therapeutics for ADHD Market Outlook, By Software-Based Therapeutic Programs (2023-2034) (\$MN)

Table 6 Global Digital Therapeutics for ADHD Market Outlook, By Video Game-Based Therapeutics (2023-2034) (\$MN)

Table 7 Global Digital Therapeutics for ADHD Market Outlook, By Mobile Application-Based Therapeutics (2023-2034) (\$MN)

Table 8 Global Digital Therapeutics for ADHD Market Outlook, By Web-Based Therapeutic Platforms (2023-2034) (\$MN)

Table 9 Global Digital Therapeutics for ADHD Market Outlook, By Age Group (2023-2034) (\$MN)

Table 10 Global Digital Therapeutics for ADHD Market Outlook, By Children (2023-2034) (\$MN)

Table 11 Global Digital Therapeutics for ADHD Market Outlook, By Adolescents (2023-2034) (\$MN)

Table 12 Global Digital Therapeutics for ADHD Market Outlook, By Adults (2023-2034) (\$MN)

Table 13 Global Digital Therapeutics for ADHD Market Outlook, By Older Adults (2023-2034) (\$MN)

Table 14 Global Digital Therapeutics for ADHD Market Outlook, By Delivery Platform (2023-2034) (\$MN)

Table 15 Global Digital Therapeutics for ADHD Market Outlook, By Smartphones (2023-2034) (\$MN)

Table 16 Global Digital Therapeutics for ADHD Market Outlook, By Tablets (2023-2034) (\$MN)

Table 17 Global Digital Therapeutics for ADHD Market Outlook, By Personal Computers (2023-2034) (\$MN)

Table 18 Global Digital Therapeutics for ADHD Market Outlook, By Wearable Devices

(2023-2034) (\$MN)

Table 19 Global Digital Therapeutics for ADHD Market Outlook, By Web-Based Platforms (2023-2034) (\$MN)

Table 20 Global Digital Therapeutics for ADHD Market Outlook, By Business Model (2023-2034) (\$MN)

Table 21 Global Digital Therapeutics for ADHD Market Outlook, By Subscription-Based (2023-2034) (\$MN)

Table 22 Global Digital Therapeutics for ADHD Market Outlook, By One-Time Purchase (2023-2034) (\$MN)

Table 23 Global Digital Therapeutics for ADHD Market Outlook, By Reimbursement-Based (2023-2034) (\$MN)

Table 24 Global Digital Therapeutics for ADHD Market Outlook, By Employer-Sponsored (2023-2034) (\$MN)

Table 25 Global Digital Therapeutics for ADHD Market Outlook, By Healthcare Provider-Sponsored (2023-2034) (\$MN)

Table 26 Global Digital Therapeutics for ADHD Market Outlook, By Application (2023-2034) (\$MN)

Table 27 Global Digital Therapeutics for ADHD Market Outlook, By Attention Training (2023-2034) (\$MN)

Table 28 Global Digital Therapeutics for ADHD Market Outlook, By Impulse Control (2023-2034) (\$MN)

Table 29 Global Digital Therapeutics for ADHD Market Outlook, By Cognitive Function Improvement (2023-2034) (\$MN)

Table 30 Global Digital Therapeutics for ADHD Market Outlook, By Behavioral Management (2023-2034) (\$MN)

Table 31 Global Digital Therapeutics for ADHD Market Outlook, By Medication Adherence Support (2023-2034) (\$MN)

Table 32 Global Digital Therapeutics for ADHD Market Outlook, By Remote Patient Monitoring (2023-2034) (\$MN)

Table 33 Global Digital Therapeutics for ADHD Market Outlook, By Other Applications (2023-2034) (\$MN)

Table 34 Global Digital Therapeutics for ADHD Market Outlook, By End User (2023-2034) (\$MN)

Table 35 Global Digital Therapeutics for ADHD Market Outlook, By Hospitals and Clinics (2023-2034) (\$MN)

Table 36 Global Digital Therapeutics for ADHD Market Outlook, By Behavioral Health Centers (2023-2034) (\$MN)

Table 37 Global Digital Therapeutics for ADHD Market Outlook, By Academic and Research Institutions (2023-2034) (\$MN)

Table 38 Global Digital Therapeutics for ADHD Market Outlook, By Homecare Settings (2023-2034) (\$MN)

Table 39 Global Digital Therapeutics for ADHD Market Outlook, By Individual Users (2023-2034) (\$MN)

Table 40 Global Digital Therapeutics for ADHD Market Outlook, By Other End Users (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

I would like to order

Product name: Digital Therapeutics for ADHD Market Forecasts to 2034 – Global Analysis By Product Type (Prescription Digital Therapeutics, Non-Prescription Digital Therapeutics, Software-Based Therapeutic Programs, Video Game-Based Therapeutics, Mobile Application-Based Therapeutics, and Web-Based Therapeutic Platforms), Age Group, Delivery Platform, Business Model, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/DC4A7DF46EFEEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC4A7DF46EFEEN.html>